木星神经科学亮点JOTrol;

2025-07-23 20:14

Jupiter Neurosciences, Inc.(JUNS) 0
iPath彭博咖啡分类指数总回报ETN(JO) 0
宝贝卷糖业(TR) 0

JOTROL™ is currently advancing toward a Phase IIa trial in Parkinson's Disease, following breakthrough preclinical data in a well-established MPTP mouse model that demonstrated meaningful improvements in motor functions. The same delivery technology is also being used in Jupiter's Nugevia™ consumer product line, launching in Q3 2025 with targeted formulations focused on cognitive health (MND), mitochondrial energy (PWR), and skin vitality (GLO).

木星神经科学亮点JOTrol;

推荐文章

美股机会日报 | 市场风格趋变？美银称接下来是小盘股的天下；金价重回5000美元上方，贵金属板块盘前齐升

新股暗盘 | 乐欣户外飙升超70%，中签一手账面浮盈4345港元；爱芯元智微涨超0.2%

高盛预计英伟达Q4营收达673亿美元 给出250美元目标股价

财报大跌背后：微软正在进行一场昂贵但精准的“利润置换”

港股IPO持续火热！下周6股排队上市，“A+H”占比一半

港股周报 | “AI红包大战”厮杀！腾讯周内暴跌近10%、阿里重挫8%，南下资金出手560亿港元大举抄底

美股机会日报 | 止跌企稳！纳指期货盘前涨约0.5%，有分析称美股连遭重挫后或回升；亚马逊盘前大跌超8%

一周财经日历 | 事关降息！美国1月非农、CPI数据下周公布；恒指季检结果下周五揭晓

高盛预计英伟达Q4营收达673亿美元给出250美元目标股价